PillRx only · Injection, Solution · Intravenous
Paricalcitol
Brands: Zemplar · Paricalcitol
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US4 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
44K
Rx · 2026 Q1
48K
Units dispensed
-42%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Accord Healthcare Inc. | unknown | 6 | SUPPLYING |
| AbbVie Inc. | unknown | 3 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- May 14, 2012RECALLRecall (Class II): Zemplar (paricalcitol) Injection, 5 mcg/mL in 2 mL multi-dose vials, 25 vial carton, Rx only, Manufactured by Hospira, …
CGMP Deviations: There is potential that Abbott's third party manufacturer, Hospira, may have applied a foreign (incorrect) stopper to vials in a specific lot of Zemplar Injection. — Recalling firm: Abbott Laboratories — Nationwide